anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The RH blood group antigens derive from two genes, RHD and RHCE, that are located at chromosomal position 1p34.1-1p36. In whites, a “cde” haplotype with a deletion of the whole RHD gene occurs with a frequency of about 40%. The relative position of the two RH genes and the location of the RHD deletion was previously unknown. A model for the RH locus was developed using RHD- and RHCE-related nucleotide sequences deposited in nucleotide sequence databases along with PCR and nucleotide sequencing. The open reading frames of both RH genes had opposite orientations. The 3′ ends of the genes faced each other and were separated by about 30,000 base pairs (bp) that contained the SMP1 gene. The RHD gene was flanked by two DNA segments, dubbed Rhesus boxes, that had about 9,000 bp length, 98.6% homology, and identical orientation. The Rhesus box contained the RHD deletion occurring within a stretch of 1,463 bp of identity. A PCR-SSP and a PCR-RFLP for specific detection of the RHD deletion was devised. The molecular structure of the RH gene locus explains mechanisms for generating RHD/RHCE hybrid alleles and the RHD deletion. Specific detection of the RHD negative genotype is now possible. The utility of the RHD PCR is limited by the incomplete knowledge of presumably rare RHD positive alleles in D negative. 1068 serologically RhD-negative samples were checked by PCR-SSP for the presence of RHD specific nucleotide sequences. 48 Samples were positive and were then assigned to specific PCR patterns or distinct RHD alleles. Seven PCR patterns were identified, three of which were not described previously, and four new RHD alleles that were RhD-negative because of nonsense or splice mutations. Another three new haplotypes represented a D el  phenotype. Three samples were mislabeled weak D or partial D. The sensitivity of current RHD PCR methods exceeded routine serology. As the molecular background of D-negative alleles causing false-positive RHD PCR in whites is more heterogeneous than anticipated, improvements in test specificity will critically depend on detecting RhD-negative RHD positive alleles.
The catastrophic antiphospholipid syndrome (CAPS) is a rare life-threatening clinical condition that represents the most severe clinical presentation of the antiphospholipid syndrome (APS). It was first described in 1992 in a group of patients that presented with multiorgan involvement and microangiopathic features of APS. Most of the current knowledge of CAPS comes from the analysis of all cases collected at the "CAPS Registry" that was created in 2000 to perform studies on this condition. Most cases are triggered by a prothrombotic situation that leads to a multiorgan thrombosis and a cytokine storm. The analysis of cases included in the "CAPS Registry" has shown that the triple therapy with anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulins is associated to a better prognosis of CAPS. The improvement of the knowledge allowed a decrease from the 50% mortality rate reported in the first series to 25-30% in the most recent publications.
EVs are characterized by their high genetic variability, with more than 120 types described to date. They are involved in mild infections, such as febrile syndromes that may be associated with respiratory and cutaneous manifestations. However, these viruses are also involved in more severe infections of the nervous system. In children infected with EV-A71, which causes mild epidemics of foot-and-mouth disease, inappropriate cytokine secretion (cytokine storm) leads to severe neurological and cardiopulmonary complications that can progress to death in children (\<5 years of age) in Asia. Many studies have focused on the inflammatory response to EV-A71 infections: some cytokines (Tumor Necrose Factor (TNF), INterFeron (INF), InterLeukine (IL)1, IL6, IL10, eotaxin,...) dosed in CSF have been associated with severe EV-A71 infections (2,5,6). Recently, a Japanese study showed an overexpression of IL-6 in the blood of children with EV-A71 foot-hand-mouth syndrome. The authors defined that a level of IL-6 ≥ 66 pg/mL could be a prognostic marker of progression to aseptic meningitis (6). In EV (other than EV-A71) meningitis, pro-inflammatory cytokines such as IL6, IL8, and INF are produced in the acute phase in CSF to control the infection, and then they decline and anti-inflammatory cytokines such as IL10 are synthesized (7). In addition, studies have shown that the production of some cytokines is greater in severe EV infections: for example, the production of IL4 and IL5 is greater in EV encephalitis than in EV skin infections (8).

However, there are very few comparative studies of cytokine expression in blood and CSF. In addition, little work has been done to study cytokine expression in meningitis due to EV other than EV-A71. In young children, these meningitis may also be complicated by encephalitis, myelitis, and even flaccid paralysis (including poliomyelitis) (2-4). The pathophysiology of these severe EV infections is currently unknown. In addition, no preventive vaccine is available against these infections (other than polio vaccine), nor are there effective curative antivirals for severe EV infections.
Decision-making capability is essential in fulfilling the need for autonomy of people with intellectual disability. In this study we aimed to examine decision-making capability regarding important social situations in people with intellectual disability at different stages of decision-making process. We studied 80 vocational school students with mild intellectual disability and 80 students of a similar age from mass vocation schools. We assessed decision-making with Important Life Decisions Task (ILDT). Students with intellectual disability obtained significantly lower scores than controls for each of the stories in ILDT as in each stage and overall final score in the decision-making process. The magnitude of difference in scores between groups varied in different stages of decision-making process. The most notable difficulties in decision-making regarding important social situations in people with intellectual disability are related to the evaluation of alternatives stage. Pattern of differences obtained in our study may be related to the content of decision-making problems.
The plasticizer di(2-ethylhexyl) phthalate (DEHP) is known to have endocrine-disrupting properties mediated by its many metabolites that form upon exposure in biological systems. In a previous study, we reported an inverse association between DEHP metabolites in the human ovarian follicular fluid (FF) and the responsiveness of the follicles to controlled ovarian stimulation during in vitro fertilization (IVF) treatments. Here, we explored this association further through molecular analysis of the ovarian FF samples. Ninety-six IVF patients from Swedish (N = 48) and Estonian (N = 48) infertility clinics were selected from the previous cohort (N = 333) based on the molar sum of DEHP metabolites in their FF samples to arrive at "high" (mean 7.7 ± SD 2.3 nM, N = 48) and "low" (0.8 ± 0.4 nM, N = 48) exposure groups. Extracellular miRNA levels and concentrations of 15 steroid hormones were measured across FF samples. In addition, FF somatic cells, available for the Estonian patients, were used for RNA sequencing. Differential expression (DE) and interactions between miRNA and mRNA networks revealed that the expression levels of genes in the cholesterol biosynthesis and steroidogenesis pathways were significantly decreased in the high compared to the low DEHP group. In addition, the DE miRNAs were predicted to target key enzymes within these pathways (FDR < 0.05). A decreased 17-OH-progesterone to progesterone ratio was observed in the FF of the high DEHP group (p < 0.05). Additionally, the expression levels of genes associated with inflammatory processes were elevated in the FF somatic cells, and a computational cell-type deconvolution analysis suggested an increased immune cell infiltration into the high DEHP follicles (p < 0.05). In conclusion, elevated DEHP levels in FF were associated with a significantly altered follicular milieu within human ovaries, involving a pro-inflammatory environment and reduced cholesterol metabolism, including steroid synthesis. These results contribute to our understanding of the molecular mechanisms of female reprotoxic effects of DEHP.
AIM: Sleep disorders are common in cancer patients and have negative consequences for patient well-being and treatment outcomes. This study aimed to investigate sleep quality and related factors in Vietnamese middle-aged cancer patients.
METHODS: A cross-sectional study was conducted on 246 middle-aged in-patient cancer patients at Vietnam National Cancer Hospital (VNCH) from 1/2021 to 7/2021. Sleep was measured by the Pittsburgh Sleep Quality Index (PSQI), with a cutoff of 5.
RESULTS: The results showed a male/female ratio of 0.85 with an average age of 52. The five most prevalent cancer types were breast, colorectal, lung, and esophagus-stomach cancer, primarily in the late stage and treated with chemotherapy. The prevalence of sleep disturbances was 58.5%. The mean PSQI score was 7.5, with sleep duration and latency of 5.4 h and 1 h, respectively. Approximately 44% of participants reported poor sleep quality, nearly 9% had daytime dysfunction, and 10.6% used sleep medication. The multivariate logistic regression results indicate that people with depression were 8.89 times more likely to have poor sleep than those without depression (95% CI:2.63-28.27, p < .001).
CONCLUSION: Sleep problems are common among middle-aged people with cancer in Vietnam, especially individuals with depression. It is necessary to have more effective approaches to sleep management for cancer patients with limited resources.
In addition to routine care, the "HomMed Telemonitor" wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months.
The cell wall is the major interface for arbuscular mycorrhizal (AM) symbiosis. However, the roles of cell wall proteins and cell wall synthesis in AM symbiosis remain unclear. We reported that a novel wall-associated kinase 13 (GhWAK13) positively regulates AM symbiosis and negatively regulates Verticillium wilt resistance in cotton. GhWAK13 transcription was induced by AM symbiosis and Verticillium dahliae (VD) infection. GhWAK13 is located in the plasma membrane and expressed in the arbuscule-containing cortical cells of mycorrhizal cotton roots. GhWAK13 silencing inhibited AM colonization and repressed gene expression of the mycorrhizal pathway. Moreover, GhWAK13 silencing improved Verticillium wilt resistance and triggered the expression of immunity genes. Therefore, GhWAK13 is considered an immune suppressor required for AM symbiosis and disease resistance. GhWAK7A, a positive regulator of Verticillium wilt resistance, was upregulated in GhWAK13-silenced cotton plants. Silencing GhWAK7A improved AM symbiosis. Oligogalacturonides application also suppressed AM symbiosis. Finally, GhWAK13 negatively affected the cellulose content by regulating the transcription of cellulose synthase genes. The results of this study suggest that immunity suppresses AM symbiosis in cotton. GhWAK13 affects AM symbiosis by suppressing immune responses.
Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (\>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib.
PURPOSE:To obtain an anticancer drug which contains as an active ingrdient a sulfate or its salt by extracting and separating a betel palm as a raw material with methanol and water and furthermore fractionating, separating and purifying it. CONSTITUTION:The title substance is an anticancer drug which contains at least one substance selected from the group consisting of sulfates and salts of NF-861, NF-86II, NPF-861A, NPF-861B, NPF-86IIA and NPF-86IIB having specified physicochemical properties. NF-861 and NF-86II are obtd. by, e.g., the following method. Namely, a betel palm as a raw material is degreased with a solvent and then extracted with methanol. Then, the extract is dried and extracted with water. The aq. soln. of the extract is purified with a non- hydrophilic org. solvent and the obtd. aq. soln. is fractionated by means of a dialysis tube. Active substances fractionated into fractions having MW of 1,000-10,000 and 100,000 or larger are named NF-861 and NF-86II, respectively. These fractions are furthermore separated and purified by means of high performance liq. chromatography to obtain NPF-861A, NPF-861B, NPF-86IIA and NPF-86IIB.
PROBLEM TO BE SOLVED: To obtain a sheet for chemical peeling capable of visually confirming the conditions of the skin through the sheet even when the sheet is applied to the skin for carrying out the chemical peeling. SOLUTION: This sheet T for chemical peeling comprises a membrane substrate 1 formed of a silicone and a chemical peeling agent subjected to coating on the whole one surface of the membrane substrate 1. The membrane substrate 1 is transparent and the conditions of the skin can visually be confirmed through the membrane substrate 1 even in the state thereof applied to the skin. Grooves 1A having a depth so as not to pass through the membrane substrate 1 are crosswise formed in the surface of the membrane substrate 1. Thereby, the membrane substrate 1 is divided into small parts 1B arranged in the form of a matrix. The respective small parts 1B can readily be excised. When unfavorable effects on the skin are produced, the small parts 1B facing to the skin can rapidly be removed.
The research aims to compare the effectiveness of Dry Needling and Ischemic Compression Technique on muscle thickness \& health related quality of life in trigger point related tension type headache. Headaches are the major health concern as one of the prevalent type of all symptoms in the worldwide population and are the cause of disabilities and hindrance in productivity of an individual.

The treatment approaches performed for trigger point related tension type headache are non-specific, vigorous, time consuming and costly. It is due to the inaccurate location of the trigger points present in cervical musculature. The studies related to comparison of specific treatment procedures to treat trigger point related tension type headaches such as dry needling and Ischemic Compression technique with the knowledge of accurate location of trigger points present in cervical musculature are lacking in Pakistani population. Hence the current study is aimed to determine the effect of dry needling and Ischemic Compression technique with the use of diagnostic ultrasound on muscle thickness, pain and health related quality of life in Trigger point related tension type headache. The study will be conducted on the tension type headache diagnosed individuals aged 20 to 50 years of age, at Physical Therapy OPD of Saifee and Ziauddin Hospital with the help of envelope method as a randomization technique. Dry needling will be performed on Group A whereas Group B will be given Ischemic Compression technique on trigger points diagnosed by Musculoskeletal Ultrasound. Patient's headache, muscle thickness and health related quality of life will be assessed by Numeric Pain rating scale, Musculoskeletal Ultrasound and Short Form-36 Questionnaire respectively. If the data will be found to be normally distributed, Pair T-test will be run for with the group analysis. Between the groups an alysis will be perform by Independent t test. In case data found to be deviated from the assumption of normal distribution, Paired T-test will be replaced by Wilcoxon test and Independent T test will be replaced by Mann Whitney U Test. The level of significance will be kept at 95% alpha-0.05.
Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
Participants will personally date and sign the informed consent before engaging in any study-related activity. Participants use a single-use lancing device to lance their finger and perform a blood glucose test with glucose test strips on the meter. Trained staff collects more blood samples for YSI and hematocrit measurement (approx. 300-350μL) using a specified lancet within 5 minutes of the first evaluable meter reading. Follow the same process to measure Ketones using the β-Ketone test strip on the same meter. The staff collects more blood samples for Imola and hematocrit measurement (approx. 500-550μL).

After subjects have completed the testing, they are then asked to complete usability questionnaires.
<P>PROBLEM TO BE SOLVED: To provide a promoter for the secretion of safe and daily ingestible insulin-like growth factor-1 (IGF-1), foods and drinks containing the same, a method for promoting the secretion of IGF-1 and the use of a polyphenol for manufacturing foods and drinks exhibiting a promoting action of the secretion of IGF-1.  <P>SOLUTION: The promoter for the secretion of IGF-1 comprises a polyphenol as an effective ingredient. The foods and drinks containing the same are also provided. The method for promoting the secretion of IGF-1 in blood or in internal organs comprises orally administering foods and drinks containing a polyphenol to a mammal. The use of a polyphenol for manufacturing foods and drinks exhibiting a promoting action of the secretion of IGF-1 is also provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for PPCI. Duration of Impella use ≤ 6 hours if used for PPCI.
We report a case of diffuse large B-cell lymphoma (DLBCL) of the gallbladder with extensive hepatoduodenal invasion, which was challenging to diagnose histologically due to a strong tendency to be necrotic. An 71 year-old man presented with upper abdominal pain and was referred to our hospital. Computed tomography revealed a distended gallbladder with air within the irregular gallbladder wall and an indistinct border with the hepatoduodenum, suggesting invasion. Esophagogastroduodenoscopy detected an ulceration in the duodenal bulb. However, histologic analysis failed to provide a definitive diagnosis due to the presence of necrotic tissue. Furthermore, direct biopsy from the gallbladder mucosa by endoscopic retrograde cholangiography revealed only necrotic tissue and no diagnosis. Contrast ultrasonography for the hepatic invasion revealed enhancement with blood flow, suggesting non-necrotic tissue. Subsequently, an ultrasound-guided core-needle biopsy was conducted to obtain tissue samples from the described lesion. The pathology showed atypical lymphocytes with irregular nuclei. Immunostaining indicated positive expression of CD10, CD20, Bcl-6, and C-Myc, consistent with a diagnosis of DLBCL. In our case, the lymphoma exhibited a strong tendency to be necrotic, making histologic diagnosis difficult. However, selective biopsy from the site of blood flow made the diagnosis possible and proved to be useful.
PURPOSE:To provide a composition for oral cavity application containing decreased amount of expensive oleanolic acid, imparted with tooth-reinforcing effect and the effect to suppress the formation of bacterial plaque and decompose the formed plaque, and effective for the prevention of dental carries, by using oleanolic acid in combination with a fluorine compound and/or dextranase. CONSTITUTION:The objective caries-preventive composition of oral application contains (A) 0.01-1d W/V% oleanolic acid and (B) 100-1,000 ppm (in terms of fluorine) of a fluorine compound (e.g. sodium fluoride, tin fluoride, sodium monofluorophosphate, etc.) and/or 2,000-100.000 unit/g of dextranase. Oleanolic acid has bactericidal and plaque-formation preventive actions, and the addition of a fluorine compound thereto promotes the bactericidal effect and imparts additional tooth-reinforcing effect. The addition of dextranase is effective to promote the plaque-formation inhibiting action and to impart additional plaque decomposition effect.
<P>PROBLEM TO BE SOLVED: To provide a new prophylactic for diabetes that is effective for prevention of diabetes and alleviation of its symptoms, particularly expectable to prevent type 2 diabetes and to alleviate the symptoms thereof.  <P>SOLUTION: It has been found that curdlan as a polysaccharide bearing β-1,3-glucoside bonds has a suppressive action on the elevation of glycemia that is very effective for prophylaxis of diabetes and for alleviation of the symptoms, and the prevention of type 2 diabetes and the alleviation of its symptoms can be expected by this actions of the above saccharide, thereby the diabetic prophylactic comprising the curdlan is created. In this invention, the curdlan is used in the form of an alkaline aqueous solution or is gelled therewith. Further, the curdlan is partially hydrolyzed in such a degree that the activity of the curdlan still remains and then is used. This diabetic prophylactic can be used as a medicinal preparation or by suitably adding to food products, or the like, for the prevention of diabetes or for the alleviation of the symptoms.  <P>COPYRIGHT: (C)2004,JPO
A compact portable transport unit (10) for shipping hyperpolarized noble gases and shielding same from electromagnetic interference and/or external magnetic fields includes a means for shifting the resonance frequency of the hyperpolarized gas outside the bandwidth of typical frequencies associated with prevalent time-dependent fields produced by electrical sources. Preferably the transport unit includes a magnetic holding field which is generated from a solenoid (20) in the transport unit (10).  The solenoid (20) includes a plurality of coil segments and is sized and configured to receive the gas chamber of a container (30). The gas container (30) is configured with a valve (32), a spherical body (33), and an extending capillary stem (35) between the valve and the body. The gas container (30) or hyperpolarized product container can also be formed as a resilient bag. The distribution method includes positioning a multi-bolus container within the transport unit to shield it and transporting same to a second site remote from the first site and subsequently dispensing into smaller patient sized formulations which can be transported (shielded) in another transport unit to yet another site.